Telehealth Rule Extended for Controlled Substance Prescribing Flexibilities

The Drug Enforcement Administration (DEA) released its proposed telemedicine rules in February and received major backlash, with a record 38,000 comments on the proposed rules.

“We take those comments seriously and are considering them carefully. We recognize the importance of telemedicine in providing Americans with access to needed medications, and we have decided to extend the current flexibilities while we work to find a way forward to give Americans that access with appropriate safeguards,” DEA Administrator Anne Milgram said in a statement issued Wednesday.

Last week, the DEA filed a draft temporary rule with the Office of Management and Budget titled “Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications.” If a telemedicine relationship was established during the COVID-19 public health emergency, the DEA will extend the in-person exam waiver for an additional 180 days.

Click here to read the full Fierce Healthcare article by Heather Landi.